secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axogen, Inc. (AXGN)
CIK:        0000805928
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0000805928-23-000003
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axogen reports preliminary Q4 2022 revenue of $36.1M, up 16% YoY ex-Avive; FY22 $138.5M, up 12%
--------------------------------------------------------------------------------

- Q4 revenue $36.1M, up 14% reported or 16% excluding Avive; FY22 $138.5M, up 9% reported or 12% ex-Avive.
- Cash and investments ~$55.0M at Dec 31, down from $59.4M at Sep 30; includes $5.3M capex for new Dayton, OH facility.
- 115 direct sales reps (flat YoY); 332 Core Accounts (+1% sequential); 968 Active Accounts (+2% sequential).
- Surpassed 75,000 Avance Nerve Graft implants since launch; BLA submission planned for H2 2023.
- Reaffirms FY22 gross margin above 80%; full FY23 outlook to be provided on March 14, 2023 earnings call.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/805928/000080592823000003/0000805928-23-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/805928/000080592823000003/axgn-20230109.htm
  HTML page:      https://secwatch.observer/filing/0000805928-23-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer